Evidence map›Paper›PMID 35549757›Full record

ArticleTrials2022

Efficacy and safety of Tibetan medicine Qingpeng ointment for acute gouty arthritis: protocol for a multi-center, randomized, double-blind, placebo-controlled trial.

Ya-Xi Shang, Xia Dong, Zhi-Min Xie, Xiao-Peng Li, Xin-Chang Wang, Ji-Yong Huang, Shu-Feng Wei, Yuan Liu, Jian-Ping Liu

Open access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in Trials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Inferring Therapeutic Targets inLife (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Ya-Xi ShangCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, 11 Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China.
Xia DongFangshan Hospital, Beijing University of Chinese Medicine, Beijing, 102499, China.
Zhi-Min XieThe Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310005, China.
Xiao-Peng LiThe Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310005, China.
Xin-Chang WangThe Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310005, China.
Ji-Yong HuangThe Second Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, 310005, China.
Shu-Feng WeiFangshan Hospital, Beijing University of Chinese Medicine, Beijing, 102499, China.
Yuan LiuLiuzhou People's Hospital, Liuzhou, 545006, Guangxi Zhuang Autonomous Region, China.
Jian-Ping LiuCentre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, 11 Bei San Huan Dong Lu, Chaoyang District, Beijing, 100029, China. liujp@bucm.edu.cn.
Beijing University of Chinese Medicine · CNZhejiang Chinese Medical University · CNLiuzhou General Hospital · CN

Funding

Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine ZYYCXTD-C-202006Project of Methodological research combining quantitative and qualitative research on the effects and risks of Chinese patent medicines 2180072120104tibet cheezheng tibetan medicine co., ltd. not applicable
6 · The paper itself

Abstract

backgroundAcute gouty arthritis (AGA) is an inflammatory arthritis clinically characterized by severe pain, swelling, and restricted movement of joints, which may cause physical disability and decrease quality of life. The use of recommended first-line treatment agents for AGA may be limited by adverse events. There has been a traditional use of alternative therapies for AGA. Tibetan medicine Qingpeng ointment is one of the on-market herbal products used for symptom relief of AGA. Previous clinical studies indicated that Qingpeng ointment can relieve pain, swelling, redness, and dysfunction of joints in patients with AGA. However, there is no rigorous randomized trial to demonstrate its benefit for AGA. In order to evaluate the efficacy and safety of Qingpeng ointment for AGA, we designed a randomized controlled trial.

methodsThis study is designed as a multi-center, randomized, double-blind, placebo-controlled trial. Two hundred and six adults with acute flare of gout, and visual analogue scale (VAS) score of joint pain ≥ 3 points will be recruited. Participants will be randomly assigned to herbal treatment or placebo group at a ratio of 1:1. Qingpeng ointment, or equal placebo ointment, will be applied topically at involved joints twice a day for consecutive 7 days. Patients in both groups would be allowed giving diclofenac sodium sustained-release tablets as rescue therapy when VAS score of joint pain ≥ 7 points during the treatment. The primary outcomes will be joint pain measured by VAS score, and joint swelling measured using width and thickness of affected joints and VAS score. Other outcome measures will be joint mobility, joint redness, C-reactive protein, serum uric acid, and the use of rescue medicine as well as adverse effect. DISCUSSION: To the best of our knowledge, this study is the first multi-center, randomized, double-blind, and placebo-controlled clinical trial to assess the efficacy of Tibetan medicine Qingpeng ointment for AGA. The findings of this study would provide evidence for its use to relieve symptoms of AGA.

trial registrationISRCTN ISRCTN34355813 . Registered on 25 January 2021.

Indexed as

Arthritis, GoutyDrugs, Chinese HerbalAdultArthralgiaDouble-Blind MethodEdemaHumansMedicine, Tibetan TraditionalMulticenter Studies as TopicOintmentsPainQuality of LifeRandomized Controlled Trials as TopicTreatment OutcomeUric AcidDrugs, Chinese HerbalOintmentsUric AcidAcute gouty arthritisGoutJoint painQingpeng ointmentRandomized controlled trialTibetan medicine

Identifiers

PMID35549757
PMCPMC9097382
OpenAlexW4280555850

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.